Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer.

ABSTRACT:

Background

Investigation remains incomplete regarding potential variations in the effect of androgen receptor pathway inhibitors, including apalutamide, based on baseline tumor burden in patients with metastatic castration-sensitive prostate cancer (mCSPC).

Methods

The authors analyzed individual participant-level data from 1052 patients with mCSPC who were randomized in the TITAN trial (apalutamide vs. placebo, both with androgen-deprivation therapy). Outcomes included radiographic progression-free survival (PFS), second PFS (PFS2), and overall survival (OS). Multivariable Cox proportional hazards regression models, with and without restricted cubic splines, were used to determine the association between apalutamide benefit and bone metastasis count or visceral metastasis.

SUBMITTER: Fukuokaya W 

PROVIDER: S-EPMC11922167 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature